You have full text access to this OnlineOpen article

Cancer

Cover image for Cancer

1 August 2010

Volume 116, Issue 15

Pages 3525–3750

  1. CancerScope

    1. Top of page
    2. CancerScope
    3. In Memoriam
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Errata
    1. You have free access to this content
    2. You have free access to this content
  2. In Memoriam

    1. Top of page
    2. CancerScope
    3. In Memoriam
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Errata
    1. You have full text access to this OnlineOpen article
      Dr. Marie-France Demierre (pages 3528–3529)

      Alan Geller and Rhoda Alani

      Article first published online: 18 JUN 2010 | DOI: 10.1002/cncr.25484

  3. Editorials

    1. Top of page
    2. CancerScope
    3. In Memoriam
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Errata
    1. You have full text access to this OnlineOpen article
      The excessive cost of early stage bladder cancer care : Are providers really to blame? (pages 3530–3532)

      Micah L. Hemani and Charles L. Bennett

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25227

      The management of early stage bladder cancer is a potential target for major healthcare savings for many reasons. To solve the problem of irrational spending on bladder cancer, more cost-effectiveness research must be undertaken, and the results of such research must be used to direct clinical practice and to influence healthcare policy reform.

    2. You have full text access to this OnlineOpen article
      How might VA-Medicare differences inform the delivery of end-of-life cancer care? (pages 3533–3536)

      Karl A. Lorenz and Jennifer L. Malin

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25101

      Impending fiscal constraints may require blunt tools to reduce expenditures, and end-of-life care has to be transformed to achieve better system efficiency. Therefore, advanced cancer care urgently needs to adopt a quality focus, to assure that reforms to payment and delivery promote both efficiency as well higher quality patient and family-centered care.

  4. Review Articles

    1. Top of page
    2. CancerScope
    3. In Memoriam
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Errata
    1. You have full text access to this OnlineOpen article
      The role of targeted agents in preoperative chemoradiation for rectal cancer (pages 3537–3548)

      Raymond C. Wadlow and David P. Ryan

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25155

      Recent trials in rectal cancer have incorporated newer cytotoxic and molecularly targeted agents into preoperative chemoradiation. A detailed overview suggests that future studies are required for the additional discovery and validation of biomarkers that predict clinical outcomes.

  5. Original Articles

    1. Top of page
    2. CancerScope
    3. In Memoriam
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Errata
    1. Disease Site

      Breast Disease
      You have full text access to this OnlineOpen article
      A study of body image in long-term breast cancer survivors (pages 3549–3557)

      Christian A. Falk Dahl, Kristin V. Reinertsen, Inger-Lise Nesvold, Sophie D. Fosså and Alv A. Dahl

      Article first published online: 13 MAY 2010 | DOI: 10.1002/cncr.25251

      Body image in breast cancer survivors was associated with many issues, was considerably stable over time, and differed very little from the body image in age-matched controls from the general population.

    2. You have full text access to this OnlineOpen article
      Breast cancer in men in the United States : A population-based study of diagnosis, treatment, and survival (pages 3558–3568)

      Linda C. Harlan, Jo Anne Zujewski, Marc T. Goodman and Jennifer L. Stevens

      Article first published online: 17 MAY 2010 | DOI: 10.1002/cncr.25153

      The use of tamoxifen in men with estrogen receptor-positive tumors was associated with decreased mortality. Although aromatase inhibitors are not recommended guideline therapy, they were being used but were not producing an associated decrease in mortality.

    3. You have full text access to this OnlineOpen article
      Identification of accrual barriers onto breast cancer prevention clinical trials : A case-control study (pages 3569–3576)

      Robert H. Houlihan, Michael H. Kennedy, Robert R. Kulesher, Stephenie C. Lemon, D. Lawrence Wickerham, Chung-Cheng Hsieh and Dario C. Altieri

      Article first published online: 5 MAY 2010 | DOI: 10.1002/cncr.25230

      A case-control study of 242 women in Massachusetts compared responses between the study group (Study of Tamoxifen and Raloxifene [STAR] trial eligible, but not enrolled) and the control group (STAR trial participants). Results of the study suggest that addressing the issues identified in this study, in the relationship between patients and clinicians, should improve accrual to breast cancer prevention clinical trials.

    4. Gastrointestinal Disease
      You have full text access to this OnlineOpen article
      Prognostic value of mucin 4 expression in colorectal adenocarcinomas (pages 3577–3586)

      Chandrakumar Shanmugam, Nirag C. Jhala, Venkat R. Katkoori, Wen Wan, Sreelatha Meleth, William E. Grizzle and Upender Manne

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25095

      Aberrant expression of mucin 4 (MUC4) in colorectal adenocarcinoma was reported previously, but its prognostic value is not determined. Therefore, for the first time, the authors report their observation that increased expression of MUC4 is an independent prognostic marker in colorectal adenocarcinomas.

    5. Discipline

      Genitourinary Disease
      You have full text access to this OnlineOpen article
      Understanding the variation in treatment intensity among patients with early stage bladder cancer (pages 3587–3594)

      John M. Hollingsworth, Yun Zhang, Sarah L. Krein, Zaojun Ye and Brent K. Hollenbeck

      Article first published online: 4 MAY 2010 | DOI: 10.1002/cncr.25221

      Medical uncertainty surrounds optimal treatment and surveillance for patients with early stage bladder cancer, and that uncertainty can lead to considerable variation in the initial management of the disease. The results from this study indicated that the physician's contribution to this treatment intensity variation is substantial and has unclear patient benefit. Reduction in these between-provider differences would yield a substantial cost savings to Medicare and may improve the value of cancer care.

    6. Disease Site

      Genitourinary Disease
      You have full text access to this OnlineOpen article
      A validated prognostic index predicting response to dexamethasone and diethylstilbestrol in castrate-resistant prostate cancer (pages 3595–3602)

      Jonathan Shamash, Justin Stebbing, Chris Sweeney, Guru Sonpavde, Steve Harland, Guy Dawkins, Cathryn Brock, Walter Abelman, Peter Wilson, Adam Sanitt, Tim Oliver and Thomas Powles

      Article first published online: 11 MAY 2010 | DOI: 10.1002/cncr.25194

      The objective of this study was to identify subgroups of patients with castrate-resistant prostate cancer (CRPC) who had a prolonged response to dexamethasone and diethylstilbestrol (DS) therapy by constructing a prognostic index. The easy-to-use, externally validated prognostic index was able to identify a subgroup of patients with CRPC who had prolonged survival only 1 month after starting DS therapy.

    7. Gynecologic Oncology
      You have full text access to this OnlineOpen article
      Overexpressed epidermal growth factor receptor (EGFR)-induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway (pages 3603–3613)

      Zhihong Ai, Juan Wang, Yudong Wang, Lihua Lu, Jianqian Tong and Yincheng Teng

      Article first published online: 11 MAY 2010 | DOI: 10.1002/cncr.25220

      In this study, epidermal growth factor receptor (EGFR) overexpression down-regulated the level of progesterone receptor isotype B and induced progestin insensitivity in human endometrial carcinoma cells by the EGFR/mitogen-activated protein kinase signaling pathway. The results indicated that an EGFR tyrosine kinase-specific inhibitor may be useful in the treatment of endometrial carcinoma.

    8. Hematologic Malignancies
      You have full text access to this OnlineOpen article
      Impact of weekend admissions on quality of care and outcomes in patients with acute myeloid leukemia (pages 3614–3620)

      Nelli Bejanyan, Alex Z. Fu, Aleksandr Lazaryan, Rao Fu, Matt Kalaycio, Anjali Advani, Ronald Sobecks, Edward Copelan, Jaroslaw P. Maciejewski and Mikkael A. Sekeres

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25086

      Despite delays in procedures and possibly longer hospital stays, acute myeloid leukemia patients admitted to a large, teaching, referral hospital over the weekend have similar clinical outcomes to those of patients admitted on weekdays.

    9. You have full text access to this OnlineOpen article
      Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma : Long-term follow-up (pages 3621–3630)

      Avichai Shimoni, Izhar Hardan, Francis Ayuk, Georgia Schilling, Djorde Atanackovic, Wolfgang Zeller, Ronit Yerushalmi, Axel Rolf Zander, Nicolaus Kroger and Arnon Nagler

      Article first published online: 5 MAY 2010 | DOI: 10.1002/cncr.25228

      Patients with multiple myeloma who developed disease recurrence after a prior autologous stem cell transplantation are reported to have a grim prognosis. The current study demonstrated with a long follow-up that a subset of these patients can be cured with allogeneic transplantation using reduced-intensity conditioning.

    10. You have full text access to this OnlineOpen article
      Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I (pages 3631–3637)

      Nikolai Velev, Jorge Cortes, Richard Champlin, Dan Jones, Gabriela Rondon, Sergio Giralt, Gautam Borthakur, Hagop M. Kantarjian and Marcos De Lima

      Article first published online: 5 MAY 2010 | DOI: 10.1002/cncr.25092

      This report, to the authors' knowledge, is the first to describe a series patients with chronic myeloid leukemia (CML) who had a threonine-to-isoleucine mutation at codon 315 (T315I) of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion (Bcr-Abl) and underwent stem cell transplantation (SCT). The outcomes presented suggest that SCT represents an effective treatment strategy for patients with this abnormality.

    11. Hepatobiliary Disease
      You have full text access to this OnlineOpen article
      Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma : Comparison with surgical resection (pages 3638–3644)

      Tatehiro Kagawa, Jun Koizumi, Sei-ichiro Kojima, Naruhiko Nagata, Makoto Numata, Norihito Watanabe, Tetsu Watanabe and Tetsuya Mine

      Article first published online: 11 MAY 2010 | DOI: 10.1002/cncr.25142

      The authors compared the survival rates of patients who received transcatheter arterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with those who received surgical resection as the initial curative treatment for hepatocellular carcinoma (HCC). In patients who had a Child-Pugh class A liver profile with early stage HCC, the probabilities of survival at 1, 3, and 5 years were similar (TACE + RFA, 100%, 94.8%, and 64.6%; surgery, 92.5%, 82.7%, and 76.9%; P = .788), suggesting that RFA combined with TACE is an efficient and safe treatment.

    12. Lung Disease
      You have full text access to this OnlineOpen article
      CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer (pages 3645–3655)

      Mauro Antonio Alves Castro, Felipe Dal-Pizzol, Stephanie Zdanov, Marcio Soares, Carolina Beatriz Müller, Fernanda Martins Lopes, Alfeu Zanotto-Filho, Marilda da Cruz Fernandes, Jose Claudio Fonseca Moreira, Emily Shacter and Fábio Klamt

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25125

      In our study, we found that cofilin expression levels (CFL1, cofilin-1; nonmuscle isoform; gene ID, 1072) are highly sensitive and specific when used as an NSCLC biomarker, and that tumor CFL1 low expression levels are associated with high overall patient survival (P = 0.001). We were also able to show that an association exists between cofilin expression levels and tumor invasion and resistance to some alkylating agents currently used to treat NSCLC.

    13. You have full text access to this OnlineOpen article
      Multicenter analysis of lung cancer patients younger than 45 years in Shanghai (pages 3656–3662)

      Jie Zhang, Su-Feng Chen, Ying Zhen, Jiaqing Xiang, Chunxiao Wu, Pingping Bao, James Luketich, Hong Hu, Xian Zhou, Junhua Zhang, Shihua Yao and Hai-Quan Chen

      Article first published online: 11 MAY 2010 | DOI: 10.1002/cncr.25100

      Lung cancer has become less rare in patients younger than 45 years; however, previous studies have provided scant and discordant data about this subgroup. The authors found several interesting characteristics of young patients with lung cancer, including median survival that is significantly shorter than in middle-aged patients.

    14. Neuro-Oncology
      You have full text access to this OnlineOpen article
      Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme (pages 3663–3669)

      John D. Hainsworth, Thomas Ervin, Elke Friedman, Victor Priego, Patrick B. Murphy, Bobby L. Clark and Ruth E. Lamar

      Article first published online: 11 MAY 2010 | DOI: 10.1002/cncr.25275

      In this phase 2 trial, sorafenib was added to oral temozolomide, after concurrent radiotherapy and temozolomide, in the first-line treatment of patients with glioblastoma multiforme. Although generally well tolerated by those patients who went on to receive maintenance therapy, the addition of sorafenib did not appear to improve the efficacy of standard therapy, primarily due to the significant number of patients who developed disease progression before maintenance therapy.

    15. You have full text access to this OnlineOpen article
      Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression (pages 3670–3673)

      Dirk Rades, Sarah Douglas, Theo Veninga, Lukas J.A. Stalpers, Peter J. Hoskin, Amira Bajrovic, Irenaeus A. Adamietz, Hiba Basic, Juergen Dunst and Steven E. Schild

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25223

      This study was performed to validate a scoring system that estimated the survival of patients with metastatic spinal cord compression. Similar to the preceding study, the difference in survival between the prognostic groups was found to be highly significant, demonstrating the validity of the scoring system. This scoring system was simplified to include 3 instead of 5 prognostic groups to facilitate its use in routine clinical practice.

    16. You have full text access to this OnlineOpen article
      Agreement between pediatric brain tumor patients and parent proxy reports regarding the Pediatric Functional Assessment of Cancer Therapy–Childhood Brain Tumor Survivors questionnaire, version 2 (pages 3674–3682)

      Hee-Jung Yoo, Young-Shin Ra, Hyeon-Jin Park, Jin-Shei Lai, David Cella, Hee-Young Shin and Dong-Seok Kim

      Article first published online: 17 MAY 2010 | DOI: 10.1002/cncr.25200

      Brain tumor-specific quality-of-life (QOL) assessment tools are useful to assess the QOL for pediatric brain tumor patients with regard to general health and brain tumor-specific well-being. The patient and parent proxy reports showed moderate-to-good agreement and yielded similar mean scores; the sole exception was a difference in emotional well-being scores.

    17. Melanoma
      You have full text access to this OnlineOpen article
      A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma (pages 3683–3691)

      Jeffrey S. Weber, Wolfram E. Samlowski, Rene Gonzalez, Antoni Ribas, Joe Stephenson, Steven O'Day, Takami Sato, Robert Dorr, Kathryn Grenier and Evan Hersh

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25119

      Median overall survival of all 68 patients treated with imexon plus dacarbazine in a phase 1-2 study was 11.7 months; of the 31 with normal lactate dehydrogenase levels, it was >22.5 months. These data support proceeding to a randomized phase 2 trial of this combination.

    18. Sarcoma
      You have full text access to this OnlineOpen article
      Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib : A phase I-II study by the Spanish group for research on sarcomas (pages 3692–3701)

      Joan Maurel, Ana Sofia Martins, Andrés Poveda, José Antonio López-Guerrero, Ricardo Cubedo, Antonio Casado, Javier Martínez-Trufero, Juan Ramón Ayuso, Antonio Lopez-Pousa, Xabier Garcia-Albeniz, Xavier Garcia del Muro and Enrique de Alava

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25111

      Low-dose chemobiotherapy combination showed promising activity in heavily pretreated gastrointestinal sarcoma tumor patients, especially those with wild type KIT genotype.

    19. Discipline

      Clinical Trials
      You have full text access to this OnlineOpen article
      The culture of faith and hope : Patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials (pages 3702–3711)

      Daniel P. Sulmasy, Alan B. Astrow, M. Kai He, Damon M. Seils, Neal J. Meropol, Ellyn Micco and Kevin P. Weinfurt

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25201

      Expressions of high expectations in early phase clinical trials have little to do with reporting knowledge and more to do with expressing optimism. This finding has implications for understanding how to protect the vulnerable and obtain valid consent from research participants.

    20. Pediatric Oncology
      You have full text access to this OnlineOpen article
      Burden of illness in adult survivors of childhood cancers : Findings from a population-based national sample (pages 3712–3721)

      Emily Dowling, K. Robin Yabroff, Angela Mariotto, Timothy McNeel, Christopher Zeruto and Dennis Buckman

      Article first published online: 24 MAY 2010 | DOI: 10.1002/cncr.25141

      Across multiple measures, adult survivors of childhood cancers have poorer health outcomes and more health limitations than similar individuals without cancer. Poorer outcomes were observed in survivors compared with similar individuals without cancer more than 30 years after diagnosis.

    21. Symptom Control and Palliative Care
      You have full text access to this OnlineOpen article
      A prospective cohort study defining utilities using time trade-offs and the Euroqol-5D to assess the impact of cancer-related lymphedema (pages 3722–3731)

      Andrea L. Cheville, Mously Almoza, Janice N. Courmier and Jeffrey R. Basford

      Article first published online: 29 APR 2010 | DOI: 10.1002/cncr.25068

      Utilities for cancer-related lymphedema are in the range of 0.80 and diminish with increasing lymphedema stage and patient body mass index. Greater expenditures for the prevention and treatment of cancer-related lymphedema are warranted.

    22. You have full text access to this OnlineOpen article
      End-of-life care for older cancer patients in the Veterans Health Administration versus the private sector (pages 3732–3739)

      Nancy L. Keating, Mary Beth Landrum, Elizabeth B. Lamont, Craig C. Earle, Samuel R. Bozeman and Barbara J. McNeil

      Article first published online: 5 MAY 2010 | DOI: 10.1002/cncr.25077

      Older men with metastatic lung or colorectal cancer treated in the Veterans Health Administration (VHA) healthcare system received less aggressive end-of-life care than similar men in fee-for-service Medicare, which may result from the absence of financial incentives for more intensive care in the VHA or because this integrated delivery system is better structured to limit potentially overly aggressive care.

    23. You have full text access to this OnlineOpen article
      Carbon-ion beam treatment induces systemic antitumor immunity against murine squamous cell carcinoma (pages 3740–3748)

      Akinao Matsunaga, Yasuji Ueda, Shigeru Yamada, Yui Harada, Hideaki Shimada, Mamoru Hasegawa, Hirohiko Tsujii, Takenori Ochiai and Yoshikazu Yonemitsu

      Article first published online: 13 MAY 2010 | DOI: 10.1002/cncr.25134

      In mice that were implanted with tumor cells, carbon-ion beam (CIB) treatment alone resulted in the efficient elimination of primary tumors and dramatically reduced tumor formation after secondary tumor challenge at a contralateral site. The antitumor effect evoked by CIB was enhanced significantly by combination with dendritic cell immunotherapy, and the results indicated that this combination warrants further investigation as a promising modality for the prevention of tumor recurrence.

  6. Errata

    1. Top of page
    2. CancerScope
    3. In Memoriam
    4. Editorials
    5. Review Articles
    6. Original Articles
    7. Errata
    1. You have free access to this content
      Erratum: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer (page 3749)

      Ji-Youn Han, Hyeong-Seok Lim, Yeon-Kyeong Yoo, Eun Soon Shin, Yong Hoon Park, Sung Young Lee, Jong-Eun Lee, Dea Ho Lee, Heung Tae Kim and Jin Soo Lee

      Article first published online: 28 APR 2010 | DOI: 10.1002/cncr.25359

    2. You have free access to this content
      Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (page 3750)

      Hagop M. Kantarjian, Richard A. Larson, Francois Guilhot, Stephen G. O'Brien, Manisha Mone, Marc Rudoltz, Tillmann Krahnke, Jorge Cortes and Brian J. Druker

      Article first published online: 21 APR 2010 | DOI: 10.1002/cncr.25358

      This article corrects:

      Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase§

      Vol. 115, Issue 3, 551–560, Article first published online: 31 DEC 2008

    3. You have free access to this content
      Erratum: Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: Results of a randomized phase 3 trial (page 3750)

      CRN Rasch, M Hauptmann, J Schornagel, O Wijers, J Buter, T Gregor, R Wiggenraad, JP de Boer, AH Ackerstaff, R Kroger, FJP Hoebers and AJM Balm

      Article first published online: 11 MAY 2010 | DOI: 10.1002/cncr.25234

      This article corrects:

SEARCH

SEARCH BY CITATION